Oncolytics reports updated GOBLET anal cancer data with 15-month median response
Oncolytics Biotech reported updated Cohort 4 data from its Phase 1/2 GOBLET study of pelareorep with atezolizumab in second-line and later squamous cell anal cancer. The company says the median duration of response is about 15 months, compared with 9.5 months for an FDA-approved retifanlimab monotherapy in a similar population, but the filing offers no revenue, earnings, or financing figures and the results remain early clinical data.
Key points
- Median duration of response is approximately 15 months; median overall survival has not yet been reached
- All patients who responded to treatment survived beyond 12 months, according to the company
- The filing says the 15-month estimate comes from the company's internal calculations for this draft
- Company cites FDA Fast Track Designation and recent FDA interactions as support for registrational development
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.